T. Rowe Price Associates, Inc. recently announced the acquisition of new stake in Replimune Group Inc (NASDAQ:REPL). The institutional investor has increased its shareholding in the Healthcare company by 0.94% to 5.67 million shares with purchase of 52966.0 shares. This fresh investment now brings its stake to 9.61% valued currently at $82.56 million. In addition, BlackRock Fund Advisors raised its holdings by 0.36 million to 3.39 million shares. And The Vanguard Group, Inc. has lifted its position by 10.27% or 0.24 million shares – to 2.53 million shares.
With over 13.89 million Replimune Group Inc (REPL) shares trading Tuesday and a closing price of $6.75 on the day, the dollar volume was approximately $93.77 million. The shares have shown a negative half year performance of -71.43% and its price on 12/05/23 lost nearly -45.21%. Currently, there are 56.68M common shares owned by the public and among those 43.34M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for REPL have a consensus price objective of $30.78. The analysts have set the share’s price value over the next 12 months at a high of $70.00 and a low of $10.00. The average price target is 81.92% above its recent price level and an upside to the estimated low will see the stock gain 32.5% over that period. But an upside of 90.36% will see the stock hit the forecast high price target while median target price for the stock is $14.00.
Insiders at the company have transacted a total of 38 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 17 of these insider trades were purchases, accounting for 586,088 shares. Insider sales of the common stock occurred on 21 occasions, with total insider shares sold totaling 174,192 shares.
The top 3 mutual fund holders in Replimune Group Inc are T Rowe Price New Horizons Fund, SPDR S&P Biotech ETF, and T Rowe Price Health Sciences Fund. T Rowe Price New Horizons Fund owns 2.44 million shares of the company’s stock, all valued at over $35.62 million. The company sold 840.0 shares recently to bring their total holdings to about 4.14% of the shares outstanding. SPDR S&P Biotech ETF bought 9671.0 shares to see its total holdings expand to 1.62 million shares valued at over $23.59 million and representing 2.75% of the shares outstanding. T Rowe Price Health Sciences Fund sold 20035.0 shares to bring its total holdings to over 1.52 million shares at a value of $22.16 million. T Rowe Price Health Sciences Fund now owns shares totaling to 2.58% of the shares outstanding.
Shares of Replimune Group Inc (NASDAQ: REPL) opened at $6.10, down -$6.22 from a prior closing price of $12.32. However, the script later moved the day high at 7.23, down -45.21%. The company’s stock has a 5-day price change of -41.46% and -66.11% over the past three months. REPL shares are trading -75.18% year to date (YTD), with the 12-month market performance down to -66.78% lower. It has a 12-month low price of $9.79 and touched a high of $29.52 over the same period. REPL has an average intraday trading volume of 801.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -39.09%, -49.91%, and -63.09% respectively.
Institutional ownership of Replimune Group Inc (NASDAQ: REPL) shares accounts for 86.58% of the company’s 56.68M shares outstanding. Mutual fund holders own 40.72%, while other institutional holders and individual stakeholders account for 45.97% and 37.80% respectively.
It has a market capitalization of $398.66M and a beta (3y monthly) value of 1.33. The earnings-per-share (ttm) stands at -$3.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.12% over the week and 10.10% over the month.
Analysts forecast that Replimune Group Inc (REPL) will achieve an EPS of -$1.04 for the current quarter, -$0.93 for the next quarter and -$3.58 for 2025. The lowest estimate earnings-per-share for the quarter is -$1.9 while analysts give the company a high EPS estimate of -$0.82. Comparatively, EPS for the current quarter was -$0.69 a year ago. Earnings per share for the fiscal year are expected to decrease by -13.92%, and 5.35% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Replimune Group Inc (REPL) as a “Strong Buy” at a consensus score of 1.11. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the REPL, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on April 17, 2023, with the firm’s price target at $44.
